These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
545 related articles for article (PubMed ID: 15627479)
21. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Rose RJ; Liu H; Palmer D; Maurice DH Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930 [TBL] [Abstract][Full Text] [Related]
22. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors. Méhats C; Tanguy G; Paris B; Robert B; Pernin N; Ferré F; Leroy MJ J Pharmacol Exp Ther; 2000 Feb; 292(2):817-23. PubMed ID: 10640323 [TBL] [Abstract][Full Text] [Related]
23. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors. Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639 [TBL] [Abstract][Full Text] [Related]
24. The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task. Giorgi M; Modica A; Pompili A; Pacitti C; Gasbarri A Behav Brain Res; 2004 Sep; 154(1):99-106. PubMed ID: 15302115 [TBL] [Abstract][Full Text] [Related]
25. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331 [TBL] [Abstract][Full Text] [Related]
26. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6). Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386 [TBL] [Abstract][Full Text] [Related]
27. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord. de Vente J; Markerink-van Ittersum M; Vles JS J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445 [TBL] [Abstract][Full Text] [Related]
28. Expression of the cAMP-phosphodiesterase PDE4D isoforms and age-related changes in follicle-stimulating hormone-stimulated PDE4 activities in immature rat sertoli cells. Levallet G; Levallet J; Bouraïma-Lelong H; Bonnamy PJ Biol Reprod; 2007 May; 76(5):794-803. PubMed ID: 17215491 [TBL] [Abstract][Full Text] [Related]
29. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK J Pharmacol Exp Ther; 1997 Jul; 282(1):505-12. PubMed ID: 9223593 [TBL] [Abstract][Full Text] [Related]
30. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts. Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161 [TBL] [Abstract][Full Text] [Related]
31. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis. Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454 [TBL] [Abstract][Full Text] [Related]
32. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Fisher DA; Smith JF; Pillar JS; St Denis SH; Cheng JB Biochem Biophys Res Commun; 1998 May; 246(3):570-7. PubMed ID: 9618252 [TBL] [Abstract][Full Text] [Related]
34. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Landells LJ; Szilagy CM; Jones NA; Banner KH; Allen JM; Doherty A; O'Connor BJ; Spina D; Page CP Br J Pharmacol; 2001 Jul; 133(5):722-9. PubMed ID: 11429397 [TBL] [Abstract][Full Text] [Related]
35. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4). Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946 [TBL] [Abstract][Full Text] [Related]
36. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Thomas RE; Armstrong DT; Gilchrist RB Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932 [TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Ko WC; Shih CM; Lai YH; Chen JH; Huang HL Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679 [TBL] [Abstract][Full Text] [Related]
38. Correlation of cell-free brain cyclic nucleotide phosphodiesterase activities to cyclic AMP decay in intact brain slices. Whalin ME; Garrett RL; Thompson WJ; Strada SJ Second Messengers Phosphoproteins; 1988-1989; 12(5-6):311-25. PubMed ID: 2856115 [TBL] [Abstract][Full Text] [Related]
39. Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Bian H; Zhang J; Wu P; Varty LA; Jia Y; Mayhood T; Hey JA; Wang P Biochem Pharmacol; 2004 Dec; 68(11):2229-36. PubMed ID: 15498513 [TBL] [Abstract][Full Text] [Related]
40. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. MacKenzie SJ; Houslay MD Biochem J; 2000 Apr; 347(Pt 2):571-8. PubMed ID: 10749688 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]